Article: Avigen Raises $27.6M Publicly To Fund Neurology Programs.

Staff Writer

Avigen Inc. raised about $27.6 million in a public offering to fund development of its programs in neurological disorders, its focus since exiting the gene therapy business a few years ago.

The Alameda, Calif., company sold 3.974 million shares at $6.94 per share. Underwriters Pacific Growth Equities LLC and UBS Investment Bank have an overallotment option to purchase 596,000 additional shares.

Avigen's stock (NASDAQ:AVGN) fell 4 cents Thursday to close at $6.90.

"We were quite well financed already, but there was an interest among investors of taking a position in Avigen," said Michael Coffee, chief business officer at ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!